Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that it will present preclinical data on its ...
Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common ...
Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead covalent PI3Kα inhibitor, and additional ...
This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...